Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 (Telitacicept) in Primary IgA Nephropathy
NCT04291781Phase 2Completed
- Sponsor
- RemeGen
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of telitacicept in IgA nephropathy (IgAN) (3 arms), sponsored by RemeGen. Primary endpoint: Change from baseline in 24-hour urine protein excretion at 24 weeks. Started Apr 2020; status: completed.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04291781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291781.